Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis

Blood

Volumn 121, Issue 8, 2013, Pages 1477-1478

  Michel, L ^a   Jean Louis, F ^a,b   Begue, E ^a   Bensussan, A ^a   Bagot, M ^a  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; MESSENGER RNA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PLS3 PROTEIN; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG;

ADULT; AGED; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CLONING; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LETTER; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEZARY CELL; SEZARY SYNDROME; T LYMPHOCYTE;

EID: 84874400876     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-460535     Document Type: Letter

References (10)

1. Begue E, Jean-Louis F, Bagot M, et al. Inducible expression and pathophysiological functions of T-plastin in cutaneous T-cell lymphoma. Blood. 2012;120(1):143-154.
2. Kari L, Loboda A, Nebozhyn M, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med. 2003;197(11):1477-1488. (Pubitemid 36682545)
3. Nebozhyn M, Loboda A, Kari L, et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood. 2006;107(8):3189-3196.
4. Booken N, Gratchev A, Utikal J, et al. Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia. 2008;22(2):393-399. (Pubitemid 351250545)
5. Tang N, Gibson H, Germeroth T, Porcu P, Lim HW, Wong HK. T-plastin (PLS3) gene expression differentiates Sezary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. Br J Dermatol. 2010;162(2):463-466.
6. Van Doorn R, Dijkman R, Vermeer MH, et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res. 2004;64(16):5578-5586. (Pubitemid 39095552)
7. Bagot M, Moretta A, Sivori S, et al. CD4 (+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood. 2001;97(5):1388-1391. (Pubitemid 32183763)
8. Ortonne N, Huet D, Gaudez C, et al. Significance of circulating T-cell clones in Sezary syndrome. Blood. 2006;107(10):4030-4038. (Pubitemid 43726811)
9. Bouaziz JD, Remtoula N, Bensussan A, Marie-Cardine A, Bagot M. Absolute CD3+CD158k+ lymphocyte count is reliable and more sensitive than cytomor-phology to evaluate blood tumour burden in Sezary syndrome. Br J Dermatol. 2010;162(1):123-128.
10. Bensussan A, Remtoula N, Sivori S, Bagot M, Moretta A, Marie-Cardine A. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sezary syndrome patients. J Invest Dermatol. 2011;131(4):969-976.